Revenue: USD324 million, a 16.5% increase from the prior year. Adjusted EBITDA: USD58 million, a 15% increase from the prior year. Gross Margin: 23.4%, up from 22.4% in the prior year period. Net Income: USD15.1 million or USD0.17 per diluted share. Adjusted EPS: USD0.48, compared to USD0.39 in the prior year period. Operating Cash Flow: Nearly USD50 million, almost double the prior year period. Fertility Revenue: USD206 million, a 22% increase from the prior year. Pharmacy Revenue: USD118 million, a 9% increase from the prior year. ART Cycles: 16,160 cycles, a 9% growth over the prior year period. Clients: 532 clients with at least 1,000 lives, up from 451 clients a year ago. Covered Lives: 6.7 million average covered lives, up from 6.35 million a year ago. Second Quarter Revenue Guidance: USD310 million to USD325 million. Full Year Revenue Guidance: USD1.185 billion to USD1.235 billion. Full Year Adjusted EBITDA Guidance: USD190 million to USD203 million.

Warning! GuruFocus has detected 2 Warning Signs with PGNY.

Release Date: May 08, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Progyny Inc (NASDAQ:PGNY) reported double-digit growth in both revenue and adjusted EBITDA, achieving record quarterly results. The company raised its full-year guidance, reflecting strong performance and consistent member engagement. Progyny Inc (NASDAQ:PGNY) expanded its product portfolio and platform, enhancing its member experience and solidifying its position in women's health and family building. The company saw a 19% increase in first-quarter revenue, excluding the impact of a large transitioning client, highlighting strong core business growth. Progyny Inc (NASDAQ:PGNY) generated nearly USD 50 million in operating cash flow in the first quarter, nearly doubling the prior year period.

Negative Points

The average number of lives in the sales pipeline is lower compared to the previous year, potentially impacting future growth. Adjusted EBITDA margin declined modestly due to incremental investments in platform and product expansion. The company anticipates variability in member engagement and treatment activity, reflecting uncertainty in the macro environment. Progyny Inc (NASDAQ:PGNY) expects gross margin expansion to be lower for the full year compared to Q1 due to additional hiring and investments. The company faces potential risks from tariffs on pharmaceuticals, which could impact costs, although current tariffs have not yet affected them.

Q & A Highlights

Q: Historical seasonality of cycles per utilizer tends to show a step up in Q2 from Q1, but the guidance implies a similar rate. Is this due to uncertainty? A: Peter Anevski, CEO: Yes, the guidance reflects the uncertainty we're seeing, which is why it appears more conservative.

Story Continues

Q: Can you elaborate on the drivers behind the gross margin expansion this quarter and expectations for the rest of the year? A: Mark Livingston, CFO: Last year's margins were suppressed due to a revenue shortfall from a mix issue. This year, we had a good quarter, but as we continue investments, some costs will impact gross margins. We expect full-year margin expansion over 2024, but not at Q1 levels.

Q: Are there any indications of employers delaying RFP processes or decision-making for the 2026 selling season? A: Michael Sturmer, President: We haven't seen a slowdown or pauses in RFP activities. Our sales goal remains to add at least a million new lives each year, and the pipeline is comparable to last year, though average lives are slightly lagging.

Q: Can you discuss the incremental adjusted EBITDA margin on incremental revenue and the path to historical levels? A: Peter Anevski, CEO: This year's incremental investments in platform and product expansion are impacting margins. These are crucial initiatives to maintain our leadership position, and we expect margins to improve as these investments mature.

Q: Which new modules are getting the most interest, and how do you see them ramping up to long-term targets? A: Peter Anevski, CEO: All modules are receiving interest, with 20% of clients adopting one or more. The menopause product sees higher engagement due to a larger addressable audience compared to maternity.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments